Christopher Oxendine
Family Medicine · Abbeville, SCNPI 1194985234
Payments from drug & device makers
Across 524 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$707
- Amgen$675
- AstraZeneca$585
- Lundbeck LLC$493
- Novo Nordisk$462
- plus $4K from 48 others
What the payments were for
- Food & beverage$8,429100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$184
How this compares
$8,429 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $132,246 |
| MounjaroTirzepatide | 79 | $81,742 |
| EliquisApixaban | 55 | $67,896 |
| Xeljanz XrTofacitinib Citrate | 13 | $66,499 |
| JardianceEmpagliflozin | 50 | $61,804 |
| TrulicityDulaglutide | 38 | $46,179 |
| EntrestoSacubitril/Valsartan | 46 | $45,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $45,551 |
| XareltoRivaroxaban | 38 | $44,689 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $35,184 |
| LinzessLinaclotide | 39 | $33,275 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $31,322 |
| MyrbetriqMirabegron | 32 | $30,057 |
| Repatha SureclickEvolocumab | 37 | $23,533 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $20,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $462 | $146,824132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $237 | $127,921117 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $151 | $96,98877 claims |
| PfizerEliquis, Nurtec Odt | $215 | $79,17267 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $268 | $50,80967 claims |
| MerckJanumet Xr, Januvia | $46 | $50,56344 claims |
| NovartisEntresto | $368 | $45,93946 claims |
| Johnson & JohnsonXarelto | $112 | $44,68938 claims |
| AbbVieLinzess | $1,260 | $33,27539 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $107 | $20,15023 claims |
| AstraZenecaBreztri Aerosphere | $585 | $9,91616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Abbeville
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.